mAbs and small-molecule inhibitors targeting VISTA are undergoing phase 1 clinical trials (e.g., NCT02812875 and NCT02671955) and have demonstrated satisfactory tolerability and anti-tumor efficacy [192, 198]. The gene discussed is VSIR; the disease is neoplasm.